{"disease":{"id":"myelodysplastic-syndrome-mds","name":"myelodysplastic syndrome mds"},"drugs":{"marketed":[{"drug_id":"cedazuridine","indication_name":"Myelodysplastic Syndromes (MDS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEDAZURIDINE","company_name":"","drug_phase":"marketed","molecular_target":"DNA methyltransferase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":45,"revenue":null,"mechanism":"Decitabine inhibits DNA methyltransferase, leading to DNA hypomethylation and cellular differentiation or apoptosis."},{"drug_id":"imetelstat","indication_name":"low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rytelo","generic_name":"IMETELSTAT","company_name":"Geron","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Rytelo works by inhibiting the activity of telomerase, an enzyme that helps cancer cells grow and divide."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02775383","title":"The National Myelodysplastic Syndromes (MDS) Study","phase":"","overall_status":"COMPLETED","enrollment_count":2115,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT07465029","title":"A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1300,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06681363","title":"Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelodysplastic Syndrome (MDS) Monitored at the Nantes University Hospital","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT03335943","title":"Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"Chinese Society of Hematology","has_results":false},{"nct_id":"NCT01929408","title":"Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients","phase":"","overall_status":"COMPLETED","enrollment_count":703,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT04064060","title":"A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":665,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT00923442","title":"Biology Studies of Hematologic Cancers","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":550,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07355478","title":"Asia Myelodysplastic Syndrome (MDS) Registry","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06971185","title":"A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":430,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT02158858","title":"A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":336,"lead_sponsor_name":"Constellation Pharmaceuticals","has_results":false},{"nct_id":"NCT05674539","title":"Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT07319793","title":"Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT02790515","title":"Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":170,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT02632708","title":"Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":153,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT03173248","title":"Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":146,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":true},{"nct_id":"NCT00528983","title":"Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":133,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT00796068","title":"Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT02730299","title":"Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Gamida Cell ltd","has_results":true},{"nct_id":"NCT04997811","title":"Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Prof. Janet Dunn","has_results":false},{"nct_id":"NCT04202003","title":"A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"TJ Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT03613532","title":"Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":102,"lead_sponsor_name":"Jacqueline Garcia, MD","has_results":false},{"nct_id":"NCT04275518","title":"A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":102,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT05665530","title":"A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT05092451","title":"Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01736683","title":"Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT00566696","title":"Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":true},{"nct_id":"NCT01599325","title":"Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT02333058","title":"Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"medac GmbH","has_results":false},{"nct_id":"NCT02966782","title":"A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT06886425","title":"Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT03849651","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":69,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":true},{"nct_id":"NCT01660607","title":"Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Stanford University","has_results":true},{"nct_id":"NCT06294275","title":"A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Longbio Pharma","has_results":false},{"nct_id":"NCT07238712","title":"Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"St. Petersburg State Pavlov Medical University","has_results":false},{"nct_id":"NCT06764511","title":"Evaluation of Response to Biosimilar Erythropoietin Alfa Therapy in Anemic Patients With Myelodysplastic Syndrome","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT03520647","title":"Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT05884333","title":"Cord Blood Transplant in Adults With Blood Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03940352","title":"HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":52,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02944955","title":"A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":52,"lead_sponsor_name":"BioLite, Inc.","has_results":false},{"nct_id":"NCT04326764","title":"Panobinostat Maintenance After HSCT fo High-risk AML and MDS","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":52,"lead_sponsor_name":"Goethe University","has_results":false},{"nct_id":"NCT07008820","title":"Patient Reported Outcomes and Patient Voice Among Patients Diagnosed With Low Risk Myelodysplastic Syndrome (LR-MDS) or Unexplained Anemia In Japan","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06465953","title":"Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT01517035","title":"Improving Blood Stem Cell Collection and Transplant Procedures","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT04429191","title":"JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Jasper Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04912063","title":"Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":40,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT06548230","title":"A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04878432","title":"STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":39,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02979366","title":"Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT03173937","title":"Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT01286038","title":"Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":37,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}